1. Home
  2. VRDN vs WHD Comparison

VRDN vs WHD Comparison

Compare VRDN & WHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRDN
  • WHD
  • Stock Information
  • Founded
  • VRDN 2006
  • WHD 2011
  • Country
  • VRDN United States
  • WHD United States
  • Employees
  • VRDN N/A
  • WHD N/A
  • Industry
  • VRDN Medical Specialities
  • WHD Metal Fabrications
  • Sector
  • VRDN Health Care
  • WHD Industrials
  • Exchange
  • VRDN Nasdaq
  • WHD Nasdaq
  • Market Cap
  • VRDN 2.7B
  • WHD 2.9B
  • IPO Year
  • VRDN N/A
  • WHD 2018
  • Fundamental
  • Price
  • VRDN $30.44
  • WHD $41.36
  • Analyst Decision
  • VRDN Strong Buy
  • WHD Buy
  • Analyst Count
  • VRDN 11
  • WHD 4
  • Target Price
  • VRDN $39.60
  • WHD $47.75
  • AVG Volume (30 Days)
  • VRDN 1.8M
  • WHD 742.4K
  • Earning Date
  • VRDN 11-05-2025
  • WHD 10-29-2025
  • Dividend Yield
  • VRDN N/A
  • WHD 1.36%
  • EPS Growth
  • VRDN N/A
  • WHD N/A
  • EPS
  • VRDN N/A
  • WHD 2.52
  • Revenue
  • VRDN $70,789,000.00
  • WHD $1,089,969,000.00
  • Revenue This Year
  • VRDN N/A
  • WHD N/A
  • Revenue Next Year
  • VRDN $37,670.06
  • WHD $29.89
  • P/E Ratio
  • VRDN N/A
  • WHD $16.32
  • Revenue Growth
  • VRDN 23340.07
  • WHD N/A
  • 52 Week Low
  • VRDN $9.90
  • WHD $33.20
  • 52 Week High
  • VRDN $30.77
  • WHD $69.98
  • Technical
  • Relative Strength Index (RSI)
  • VRDN 77.12
  • WHD 52.17
  • Support Level
  • VRDN $28.33
  • WHD $39.16
  • Resistance Level
  • VRDN $29.58
  • WHD $44.35
  • Average True Range (ATR)
  • VRDN 1.32
  • WHD 1.73
  • MACD
  • VRDN 0.18
  • WHD -0.36
  • Stochastic Oscillator
  • VRDN 95.37
  • WHD 40.89

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

About WHD Cactus Inc.

Cactus Inc is engaged in the designing, manufacturing, and sale of wellheads and pressure control equipment. Its principal products include Cactus SafeDrill wellhead systems, conventional wellheads, and production valves among others. The company also provides mission-critical field services, including service crews to assist with the installation, maintenance, and safe handling of the wellhead and pressure control equipment, as well as repair services for equipment that it sells or rents. It sells or rents its products principally for onshore unconventional oil and gas wells that are utilized during the drilling, completion (including fracturing), and production. The company has two operating segments; Pressure Control, which generates key revenue and Spoolable Technologies.

Share on Social Networks: